FibroBiologics
FBLG
50 hedge funds and large institutions have $17.2M invested in FibroBiologics in 2024 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 6 closing their positions.
550% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 6
231% more capital invested
Capital invested by funds: $5.18M → $17.2M (+$12M)
194% more funds holding
Funds holding: 17 → 50 (+33)
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
0.45% more ownership
Funds ownership: 0.07% → 0.53% (+0.45%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$8.64M |
| 2 |
State Street
Boston,
Massachusetts
|
+$3.59M |
| 3 |
CFP
Cascade Financial Partners
San Diego,
California
|
+$3M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.91M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.76M |
| 2 |
HF
HRT Financial
New York
|
-$619K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$337K |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
-$277K |
| 5 |
Citigroup
New York
|
-$234K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HF
51
HRT Financial
New York
| – | -$619K | -2,867 | Closed |
|
|
ECM
52
ExodusPoint Capital Management
New York
| – | -$277K | -1,280 | Closed |
|
|
PD
53
Point72 (DIFC)
Dubai,
United Arab Emirates
| – | -$172K | -796 | Closed |
|
54
Balyasny Asset Management
Chicago,
Illinois
| – | -$154K | -712 | Closed |
|
|
CSS
55
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$97.1K | -449 | Closed |
|
56
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$12 | -54 | Closed |
|
FBLG Hedge Fund Activity: Q2 2024 in Review
50 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in FibroBiologics (FBLG) for Q2 2024, worth a combined $17.2M — up 231% from $5.18M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new FBLG positions and 6 closed out — a net gain of 33 holders — while 6 added to existing stakes and 4 trimmed.
The largest buyer was BlackRock, adding an estimated $8.64M. The largest seller was Millennium Management, cutting an estimated $1.76M.
- 50 institutional investors held FibroBiologics (FBLG) as of Q2 2024, up from 17 in Q1 2024.
- Funds reported $17.2M of FibroBiologics stock for Q2 2024, up 231% quarter-over-quarter.
- 39 funds opened new FibroBiologics positions in Q2 2024 and 6 closed out, a net change of +33 holders.
- The largest FibroBiologics buyer in Q2 2024 was BlackRock, an estimated $8.64M added.
- The largest FibroBiologics seller in Q2 2024 was Millennium Management, an estimated $1.76M sold.
Based on aggregated 13F filings for Q2 2024.